key: cord-0915526-gxh8m9rm
authors: Xiang Ong, Sean Wei; Tham, Sai Meng; Koh, Lin Pin; Dugan, Christopher; Khoo, Bo Yan; Ren, Dongdong; Sutjipto, Stephanie; Lee, Pei Hua; Young, Barnaby Edward; Lye, David Chien
title: External validation of the PRIORITY model in predicting COVID-19 critical illness in vaccinated and unvaccinated patients
date: 2022-02-10
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.01.031
sha: 7694b19c4c648e409d23462d595522c2791a1bcd
doc_id: 915526
cord_uid: gxh8m9rm

OBJECTIVES: Predictive scores are important tools for triage of COVID-19 patients. The PRIORITY score is advantageous as it does not require laboratory and radiologic information, however the original development and validation cohorts studied only unvaccinated patients in early 2020. We aimed to externally validate the PRIORITY score in a cohort of COVID-19 patients with novel Delta and Omicron variants and mixed vaccination status. METHODS: 410 patients were included in a cross-sectional sampling of all patients admitted in the National Centre of Infectious Diseases on 27-October-2021. A further 102 patients and 136 patients with vaccine-breakthrough Delta and Omicron variant infection from April-August and December-2021 respectively were also included. Variables on admission were collected retrospectively from the medical record and used to calculate the probability of deterioration using the PRIORITY model. RESULTS: Of the total 648 included patients, 447 (69.0%) were vaccinated. Mean age was 61.6 (SD ±19.0) years, and 268 (41.4%) patients were female. 112 (17.3%) met the primary outcome of developing critical illness or mortality. Performance of the score in this cohort was comparable to the original cohorts, with an AUC for all patients of 0.794 (95% CI 0.752–0.835, p<0.001), regression coefficient of 1.069 and intercept of 0.04. Subgroup analysis of unvaccinated and vaccinated patients showed that performance was superior in vaccinated individuals, with AUC of 0.684 (95% CI 0.608–0.760, p<0.0001) and 0.831 (0.772–0.891, p<0.0001) respectively. CONCLUSIONS: Our data support the continued use of the PRIORITY score in this era of novel variants and increased vaccination uptake.

Predictive scores are important tools for triage of COVID-19 patients. The PRIORITY score is 19 advantageous as it does not require laboratory and radiologic information, however the original 20 development and validation cohorts studied only unvaccinated patients in early 2020. We aimed to 21 externally validate the PRIORITY score in a cohort of COVID-19 patients with novel Delta and Omicron 22 variants and mixed vaccination status. were also included. Variables on admission were collected retrospectively from the medical record 28 and used to calculate the probability of deterioration using the PRIORITY model. 29

Of the total 648 included patients, 447 (69.0%) were vaccinated. Mean age was 61.6 (SD ±19.0) years, 31 Our data support the continued use of the PRIORITY score in this era of novel variants and increased 39 vaccination uptake. We calculated probability of deterioration for each patient using the same PRIORITY risk formula 80 outlined by Martínez-Lacalzada and colleagues in their paper. Scores were calculated retrospectively 81 using data from the medical record as recorded by managing physicians upon hospital admission. We 82 used the same primary outcome of critical illness as defined by intensive care unit (ICU) admission or 83 mortality, and evaluated performance of the risk score by calculating the area under the receiver 84 operating characteristic curve (AUC) in the entire cohort, and in subgroups of vaccinated and 85 unvaccinated patients. "Vaccinated" was defined as receipt of two COVID-19 vaccine doses ≥2 weeks 86 before illness onset; all other patients were considered "unvaccinated". Outcome data were censored 87 upon discharge or at 28 days after illness onset. 88

We also calculated the minimum sample size required for validation of the existing PRIORITY model 89 using methods and STATA code provided by Riley In this study, we validated the published PRIORITY risk score in a cohort of hospitalised COVID-19 119 patients, and demonstrated comparable performance between vaccinated and unvaccinated patients. 120

Model performance was also comparable to the cohorts in Martínez-Lacalzada and colleagues' original 121 paper (C-statistic 0.823 and 0.794 in the development and validation cohorts respectively, compared 122 to 0.794 in our cohort) (1), despite the smaller sample size, differences in demographics between 123 study cohorts, and changes in viral variants. In our study cohorts, almost all cases were due to Delta 124 or Omicron variants (11). The PRIORITY score remains a promising risk prediction tool, as its ease of 125 administration permits its use on a mass scale in the community without requirement for radiographic 126 or laboratory parameters, which is especially important during periods of disease surges and stretched 127 healthcare capacity. The authors of the original paper have provided a freely available online 128 calculator, available at (https://www.evidencio.com/models/show/2344), to facilitate adoption in 129 clinical practice. Our data support the continued use of the PRIORITY score in this era of novel VOCs 130 and increased vaccination uptake. 131 J o u r n a l P r e -p r o o f BEY reports personal fees from Roche and Sanofi, outside the submitted work. All other authors 133 declare no competing interests. SWXO has full access to all the data in the study and takes 134 responsibility for the integrity of the data and the accuracy of the data analysis. 

Predicting critical illness on initial diagnosis of COVID-19 based on easily obtained clinical 140 variables: development and validation of the PRIORITY model

Virological and 143 serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center 144 cohort study

Clinical and virological features of 146 SARS-CoV-2 variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.315 147 (Beta), and B.1.617.2 (Delta)

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a 149 retrospective cohort study in Ontario

SARS-CoV-2 Omicron variant shows 151 less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-152 expressed cells

Early assessment of the 154 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Comparison of the clinical 157 features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and 158 Delta variants

Minimum sample 160 size for external validation of a clinical prediction model with a binary outcome

Topic Group 163 'Evaluating diagnostic t, et al. Calibration: the Achilles heel of predictive analytics

Impact of Delta 168 Variant and Vaccination on SARS-CoV-2 Secondary Attack Rate Among Household Close Contacts